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Clinical Challenges and Unmet Needs in the
Management of Complicated Intra-abdominal Infections
JOHN E. MAZUSKI

ABSTRACT
Background: Management of complicated intra-abdominal infections involves invasive procedures for control of the source of the infection and antimicrobial therapy directed against
gram-negative and anaerobic pathogens. Application of these management principles to the
individual patient is essential to optimize the patient’s chances for recovery, while also avoiding unnecessary therapy that may have no clinical benefits, or that may carry risk.
Methods: Based on a review of the literature, treatment guidelines, and expert opinion, the
challenges of managing patients with complicated intra-abdominal infections are summarized
using a patient stratification approach: “Lower risk” of treatment failure and death vs. “higher
risk.”
Results: Risk factors for treatment failure and death can be grouped into several categories,
including the patient’s pre-existing medical comorbidities and physiological response to the
infection, the extent of the intra-abdominal infection, and the presence of specific pathogenic
microorganisms. These latter factors may be more useful than the Acute Physiology and
Chronic Health Evaluation (APACHE) II score in evaluating specific management strategies
for patients with complicated intra-abdominal infections. The principal goal of treatment in
lower-risk patients is to avoid morbidity related to source control procedures and antimicrobial therapy. Limitation of the scope of source control procedures and utilization of short-duration, narrow-spectrum, low-toxicity antimicrobial regimens is advisable to avoid adverse
drug reactions and selection of resistant organisms. For higher-risk patients, the goal is to develop improved management modalities, so that morbidity and mortality are reduced. The
recommended approach for higher-risk patients is to identify the most appropriate source
control procedure and antimicrobial therapy, as dictated by the patient’s specific risk factors,
and to utilize the optimal tools of critical care medicine to treat these critically ill, septic patients. The emergence of bacterial resistance also must be considered when selecting antimicrobial therapy for both low risk and high risk patients with intra-abdominal infections. Because aminoglycoside regimens are becoming less favored, and optimal therapeutic strategies
have not been standardized, the use of new treatment options (e.g., tigecycline) may be valuable when managing patients with intra-abdominal infections. especially for resistant isolates.
Conclusions: The management of lower-risk patients with intra-abdominal infections is distinct compared with patients at higher risk due to compromised physiological status, extent
of intra-abdominal infection, or presence of nosocomial pathogens associated with higher-
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risk patients. Carefully designed, multidisciplinary-sponsored, clinical trials in patients with
specific clinical risk factors are needed to better assess the role of various antimicrobial regimens in the treatment of higher-risk patients with intra-abdominal infections.

I

NTRA-ABDOMINAL INFECTIONS result from the
growth of bacteria in sterile regions of the abdomen such as the peritoneal cavity, the retroperitoneum, or solid organs, or from the
uncontrolled overgrowth of microorganisms
within the hollow viscera, where the normal
resident flora coexists in a commensal relationship with the host. These infections ordinarily
occur in association with an inflammatory
process as either cause or consequence of the
infection. As such, there is a wide variety of disparate pathological processes that can be called
intra-abdominal infections, ranging from localized appendicitis to the diffuse inflammation of
the abdominal cavity characterized as tertiary
peritonitis [1,2].
The term “complicated” intra-abdominal infections is used to distinguish infections that require an invasive procedure for source control
from “uncomplicated” infections, which can be
treated medically without an invasive intervention [1]. This distinction is most applicable
when there is a clear dichotomy in the pathophysiology and microbiology of the infections.
Disorders such as secondary peritonitis and intra-abdominal abscesses generally arise from
the resident intestinal flora and are polymicrobial in nature; these infections are generally
treated with an invasive procedure. In contrast,
disorders such as primary peritonitis and peritoneal catheter-associated infections are not
usually due to enteric pathogens, and are usually monomicrobial; such infections are usually
treated medically. However, this distinction,
having been based on operational rather than
pathophysiological differences, becomes somewhat artificial when applied to certain disorders, particularly those characterized by localized perforation of a hollow viscus. Thus,
perforated diverticulitis or a peri-appendiceal
phlegmon would be classified as uncomplicated if treated non-operatively by one practitioner, but as complicated if treated surgically
by another. The lines between complicated and
uncomplicated infections are also blurred by
the use of percutaneous, radiologically-guided

procedures for both diagnostic and therapeutic purposes. For instance, would the diagnostic “fine-needle” aspiration of a pancreatic
phlegmon to ascertain the presence of infection
suffice for that infection, if present, to be classified as “complicated?” Alternatively, would
a drain have to be left in place for that distinction to be made? This review does not adhere
to a strict separation of intra-abdominal infections into uncomplicated and complicated varieties. The discussion will focus on those intra-abdominal infections treated typically by
surgeons, whether or not an initial surgical intervention is performed.
The optimal treatment of patients with intraabdominal infections includes a source control
procedure for drainage or control of the infectious focus, and adjuvant antimicrobial therapy
to treat residual infecting organisms [2–5]. In
some patients with uncomplicated intra-abdominal infections, the definitive source control procedure is deferred, and there is sole reliance on antimicrobial agents and the host
response to control the infection. This latter approach applies to the patients described above,
who are treated nonoperatively for a phlegmon
resulting from acute diverticulitis or appendicitis. Another crucial element in the care of
these patients is physiological support of organ
function during the acute phase. This includes
appropriate fluid resuscitation and other interventions needed to maintain critical perfusion
of organs being pushed to their physiological
limits by the host response to the infection [2].
Overall, the treatment paradigm of appropriate source control and antimicrobial therapy
has produced generally satisfactory results.
One epidemiological survey of patients with
complicated intra-abdominal infections found
an overall mortality rate of 6.0%, a postoperative abscess rate of 10.2%, and a re-operation
rate of 12.5% [6]. Nonetheless, these data reflect
the outcome of a heterogeneous group of patients at variable risks of treatment failure and
death. Thus, the generally good results obtained in lower-risk patients, such as the young
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patient with complicated appendicitis, contrasts with the much poorer results observed in
higher-risk patients, such as the elderly individual with multiple medical comorbidities
who develops generalized peritonitis following
disruption of a colonic anastomosis.
Although stratifying the population of patients with intra-abdominal infections into
lower-risk and higher-risk patients is a simplification, it is helpful in discussing their respective, differing management challenges. The
central concept adhered to in this review is that
the management approach should reflect the
expected outcome, and that the issues in management differ between patients at lower risk
and those at higher risk. Thus, clinical investigations should address different questions in
lower-risk and higher-risk patients.
The topics that will be discussed can be
grouped into three general areas: Distinguishing lower-risk from higher-risk patients, and
understanding how distinct risk factors might
influence therapeutic decision-making; minimizing the morbidity of the specific procedures
employed and simplifying the type of antimicrobial therapy used for lower-risk patients
with expected good clinical outcomes; and determining how to utilize different invasive
strategies appropriately for source control and
to tailor antimicrobial therapy to the likely
pathogens that will be present in higher-risk
patients, in whom mortality is substantial.

CHARACTERIZING PATIENT RISK
Before describing separate management
strategies for lower-risk and higher-risk patients with intra-abdominal infections, it is necessary to consider how to stratify patients into
these different risk categories. Stratification can
best be based on specific clinical risk factors
that predict adverse clinical outcomes, identified through the use of multivariate analyses.
For patients with complicated intra-abdominal
infections, a number of studies have identified
risk factors that are associated with treatment
failure or death.
A question that might arise is which clinical
endpoint, treatment failure or death, is more
appropriate for risk stratification. There are ad-

S-51

vantages and disadvantages to the use of either
endpoint. At first glance, mortality might seem
to be the most logical endpoint. However,
death is a relatively infrequent outcome for patients with intra-abdominal infections, especially for low risk infections, and may ultimately be influenced more by factors related to
the patient’s underlying physiological condition than by factors related to the infection itself. Conceivably, stratification on the basis of
risk factors that predict treatment failure might
be more likely to identify a group of patients
for whom altered therapeutic interventions
would impact outcome favorably. However,
treatment failure can be a somewhat nebulous
endpoint, and needs to be described carefully.
For example, if adverse outcomes such as superficial surgical site infections are included as
treatment failures in the analyses, then the
identified risk factors may pertain primarily to
these minor complications, and not to major
complications such as an intra-abdominal abscess or a need for re-operation.
A number of studies [7–12] analyzing risk
factors for death and treatment failure were reviewed as part of the revised Surgical Infection
Society (SIS) guidelines on antimicrobial therapy for intra-abdominal infections [3,4]. These
risk factors are summarized in Table 1. To a
first approximation, these data suggest that the
same general types of risk factors influence
both treatment failure and death, few of which
relate directly to the infection itself or to the
treatment modalities utilized. The Acute
Physiology and Chronic Health Evaluation
(APACHE) II score was associated with an
adverse outcome in all of the studies, and was
the most powerful marker of both treatment
failure and death. The APACHE II score is
based on the patient’s age, acute physiological
derangements, and the chronic health problems as determined within 24 h of the reference
time point. As such, the APACHE II score reflects a compilation of the severity of the infection, the host response to the infection, and
the patient’s underlying comorbid medical
conditions. Several other risk factors identified
in these studies also pertained primarily to the
patients’ comorbidities. For instance, hypoalbuminemia was found to be a risk factor for
a poor outcome in patients with intra-abdomi-
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TABLE 1.

INDEPENDENT RISK FACTORS

FOR

MORTALITY

Mortality (five studies)

OR

TREATMENT FAILURE

Treatment failure (two studies)

APACHE II Score#

APACHE II Score*

Age*

Age

Hypoalbuminemia*

Hypoalbuminemia

Hypocholesterolemia

Prolonged pre-study length of hospitalization

Malnutrition
Preoperative Organ Impairment
NYHA Functional Class
Liver Disease
Malignant Disease
Renal Disease
Corticosteroid Therapy
Mannheim Peritonitis Index
Unsuccessful Operation
#Identified in five studies.
*Identified in two studies.
Adapted from [4], based on [7–12].

nal infections, and is, in fact, a factor for identifying patients at risk for an adverse outcome
following any surgical procedure [13]. Nonetheless, these other risk factors are reflected to
some extent in the APACHE II score, and this
score proved to be a more consistent predictor
of outcome than any marker of the patient’s
underlying medical condition considered separately.
There are several difficulties related to the
use of the APACHE II score for stratifying patients with intra-abdominal infections. It is
somewhat cumbersome to use, and is subject
to inter-observer variability. Furthermore, if
this score is calculated after a patient has first
been resuscitated in the emergency department or operating room, as occurs frequently
in the patient with an intra-abdominal infection, the score is artifactually lowered. However, the major issue is whether or not the
APACHE II score provides information that is
unique to patients with intra-abdominal infections, and can be used to guide specific
therapy for these patients. Given that the
APACHE II score is a general marker of critical illness, it seems possible that this score
would be more useful in determining the general treatment approach to be followed in the
intensive care unit than in delineating specific

source control procedures or antimicrobial
regimens to be used in a given patient.
In the studies cited, a few risk factors pertained more to the infection, and to the treatments utilized, than to the patient’s physiological status or underlying medical condition.
These risk factors might have more direct applicability to specific therapies selected for patients with intra-abdominal infections. It is interesting that the source of the infection is not
found to be an independent risk factor in these
analyses. Thus, the lower mortality rate of patients with complicated appendicitis [6] may be
related to their younger age and healthier condition as to the extent of peritoneal contamination, compared to patients with other types
of intra-abdominal infections.
The source of the infection may contribute
indirectly to risk, however, as an influence on
the extent of the infection. In one of the risk factor analyses, the Mannheim Peritonitis Index,
a parameter describing the extent of the intraabdominal infection, was found to be an independent risk factor [10]. One observational trial
suggested limiting the duration of antimicrobial therapy based on the extent of the peritoneal infection [14], even though it did not use
the Mannheim Peritonitis Index. The use of repeat laparotomy or multiple reoperations has
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also been based, at least to some degree, on the
extent of the peritoneal infection [2]. Thus,
stratifying patients through the use of a reproducible system to describe the extent of the intra-abdominal infection could have direct utility
for future investigations into their management.
One risk factor identified as a predictor of
mortality is an unsuccessful initial operation
[12]. It is often uncertain if the initial failure is
due to technical error or due to the widespread
nature of infection. In any case, these data provide some validation for the concept that an
optimal source control procedure is crucial to
achieving a good outcome in patients with
complicated intra-abdominal infections. The
challenge, then, is in determining how to
achieve successful initial source control, considering the multiplicity of technical approaches that are available, the lack of data
regarding comparative efficacy of operative
procedures, and the major influences of experience and opinion in clinical surgical practice.
There is increasing recognition that patients
with intra-abdominal infections due to organisms acquired in health care institutions (i.e.,
nosocomial intra-abdominal infections) are at
higher-risk for treatment failure and death. Although not noted in the other multivariate
analyses, the study of Barie et al. [11] identified
a prolonged pre-study duration of hospitalization as a risk factor for treatment failure. This
clinical parameter may be a surrogate for the
acquisition of resistant flora. Several studies
have affirmed a role of resistant microorganisms in treatment failure [15–17]. In particular,
Montravers et al. [17] used a multivariate analysis to show that the presence of organisms resistant to the empiric antimicrobial regimen
chosen is an independent predictor of mortality in patients with postoperative peritonitis.
The choice of empiric antimicrobial therapy
may therefore play a role in determining clinical outcome. Thus, stratifying patients according to their likelihood of harboring resistant
pathogens acquired nosocomially could be an
approach to guiding the selection of specific antimicrobial therapy.
In summary, challenges remain in developing risk stratification of patients with complicated intra-abdominal infections. Although the
APACHE II score is a powerful marker of treat-
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ment failure and death, factors describing the
extent of the intra-abdominal infection and the
likelihood of resistant pathogens could potentially be more useful than the APACHE II score
in evaluating specific management strategies
for these patients.

MANAGEMENT OF LOWER-RISK
PATIENTS
Lower-risk patients with community-acquired intra-abdominal infections can usually
be managed successfully using the standard
approach of an appropriate source-control procedure and adjuvant antimicrobial therapy directed against gram-negative Enterobacteriacae
and anaerobic pathogens. The outcome of
lower-risk patients can be inferred from the results of antibiotic registration trials carried out
in patients with complicated intra-abdominal
infections. In many of these trials, lower-risk
patients with community-acquired infections
were predominately or exclusively enrolled
and evaluated. With the exception of a few trials emphasizing higher-risk patients, mortality
was nearly always less than 5% in these trials,
and was often zero. Typically, success (clinical
cure) rates ranged from 85–100% [4]. Many of
the treatment failures recorded were relatively
minor, such as the development of a superficial surgical site infection in a patient whose
surgical incision was closed primarily. Although substantive treatment failures do occur
occasionally in these lower-risk patients, the
low incidence of these complications would
make it unlikely that major changes in the standard treatment approach would be rewarded
by significant improvements in outcome.
If the standard approach remains valid for
lower-risk patients with community-acquired
intra-abdominal infections, what then are the
unmet needs in managing this group of patients? Conceivably, these could be the patients
for whom less aggressive interventions might
be warranted under selected circumstances, in
order to minimize morbidity. Thus, with regard to source control procedures, the challenge would be to determine if less invasive
procedures could be used, or if it is possible to
defer a definitive source control procedure en-
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tirely in selected patients. Obviously, this could
only be done if there is no compromise to the
generally good overall outcome of this group
of patients. With regard to antimicrobial therapy, the goal would be to utilize a regimen that
is not only effective, but also as safe as possible. Within this context, safety applies not only
to the patient, in avoiding a potentially toxic
regimen, but also to the community at large, in
avoiding a regimen likely to encourage the development of resistant pathogens. The ideal
regimen would also be simple to administer
and perhaps amenable for use in the outpatient
setting. The challenges of providing appropriate source control and antimicrobial therapy to
lower-risk patients with community-acquired
infections will be discussed separately.
Source control for lower-risk patients with
community-acquired intra-abdominal infections
The optimal source-control procedure for patients with intra-abdominal infections has been
characterized by Marshall [2] as “drainage of abscesses or infected fluid collections, debridement
of necrotic infected tissue, and definitive measures to control a source of ongoing microbial
contamination and to restore anatomy and
function.” Although source control is considered central to the treatment of complicated intra-abdominal infections, and is included as a
necessary component in this definition, there
are clearly patients with intra-abdominal infections who are managed successfully without
an initial source control procedure. For instance, many patients with acute diverticulitis
have traditionally been managed non-operatively, as have some patients with perforated
duodenal ulcers. In addition, some patients
with complicated appendicitis are being
treated with a less invasive approach, or even
an initial non-operative approach. Some of the
trends in the management of patients with appendicitis will now be detailed, as an example
of how the approach to source control in lowerrisk patients with community-acquired intraabdominal infections might be altered in order
to decrease morbidity.
Appendicitis is probably the most common
intra-abdominal infection treated by surgeons.
The pathophysiology of acute appendicitis has
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long been assumed to be obstruction of the appendiceal lumen, with subsequent distention
and bacterial overgrowth within the lumen,
which eventually results in gangrene or perforation of the appendix. Some would argue that
acute appendicitis is not an intra-abdominal infection until there is actual spread of bacteria
beyond the appendiceal wall through perforation. For purposes of this discussion, however,
all aspects of source control for appendicitis
will be considered, although issues related to
perforated and non-perforated appendicitis
will be discussed separately.
The therapy of perforated appendicitis is undergoing evolution, in part because modern
imaging tools allow the extent of the infection
to be characterized as part of diagnosis. Traditionally, appendectomy had been recommended for all patients with perforated appendicitis, except for those with a palpable
mass presumed due to a mature peri-appendiceal abscess; those patients were treated with
antimicrobial therapy and drainage of the abscess, with subsequent interval appendectomy.
However, many patients with perforated appendicitis are now being diagnosed radiographically; these patients do not have a palpable mass or a mature abscess. Rather, they
have a peri-appendiceal phlegmon or, at most,
a small abscess in the region of the appendix.
How should a patient with a peri-appendiceal abscess or phlegmon be treated now that
the diagnosis can be made accurately? The
standard operative approach may necessitate a
large procedure (e.g., right hemicolectomy)
due to extensive inflammation around the cecum. Initial non-operative management might
allow inflammation to subside sufficiently,
such that appendectomy would become feasible after an appropriate interval.
A number of studies have evaluated this approach to management of patients with complicated appendicitis. Oliak et al. [18] reported
a series of 77 patients with perforated appendicitis and no palpable mass. These patients
were initially treated nonoperatively, in many
cases without drainage of a radiologically-confirmed abscess. Overall, there was no difference in outcome between these patients and a
historical group of patients without a palpable
mass who were treated with an immediate op-
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erative procedure. Nonoperative management
was successful in 95% of the patients; 12% of
the patients had major complications, some of
which were the result of an interval appendectomy performed subsequently. These data parallel those from an earlier series reported by
Hoffmann et al. [19], as well as a recent small
prospective randomized study by Kumar and
Jain [20]. However, Samuel et al. [21] published
a series of 48 children treated nonoperatively,
and found that 21% required early operative
intervention because of a failure of medical
management. They concluded that early operative management was associated with fewer
complications than was initial medical therapy.
Thus, the appropriate role of nonoperative
management of patients with perforated appendicitis is still being debated.
If non-operative management for perforated
appendicitis is utilized, what is the role of interval appendectomy, which is recommended
by many surgeons, particularly pediatric surgeons [22]? Again, a definitive answer is not
available, due to the lack of large-scale, prospective trials. Several authors suggest that this procedure is superfluous because the incidence of
recurrent appendicitis in these patients is actually quite low, less than 20% [20,23–27]. It
has also been suggested that recurrent appendicitis, when it does occur, has a more benign
presentation than when it was diagnosed originally [24,27]. Moreover, interval appendectomy has complications associated with its use
[18,26,28]. An argument in favor of interval appendectomy has been made based on the fact
that important pathological findings are often
found in the resected specimen and that an underlying tumor or other important lesion might
still be present even with negative diagnostic
imaging studies [21,29,30].
If deferring or abandoning a source control
procedure for perforated appendicitis is a potentially viable option, what should be the role
of appendectomy for the larger group of patients who have non-perforated appendicitis?
Clearly, the disease process is less severe in
these patients than it is in patients who have
had a perforation; yet, much of the interest in
utilizing less aggressive therapy for source control has focused only on patients who have perforated appendicitis. The reluctance to consider
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nonoperative management for patients with
acute, non-perforated appendicitis may reflect
the longstanding concept that this pathological
process inevitably progresses to perforation
and potentially fatal peritonitis. However, this
concept is likely based more on surgical lore
than on the actual natural history of the disease
process [31].
Thus, there are few data available with regard to the nonoperative management of acute,
non-perforated appendicitis. The most-cited
reference is a retrospective review of successful nonoperative management in nine military
patients [32]. Additionally, a small prospective,
randomized trial by Eriksson and Granstrom
demonstrated initial success with nonoperative
management in 95% of patients with acute appendicitis, but subsequent recurrence of appendicitis in 35% [33]. Although these data suggest that nonoperative management of acute
appendicitis is reasonably safe, there are extensive data documenting that appendectomy
for acute, non-perforated appendicitis is also
safe. The overall mortality over a ten-year period in the Swedish population was 0.8/1,000
appendectomies performed [34]. The mortality
rate approached 1% only in elderly patients.
Another study from Sweden documented that
only 1.3% of patients who had undergone appendectomy underwent a subsequent surgical
procedure for adhesive small bowel obstruction after 30 years of follow-up [35]. Although
this rate was six-fold higher than that of the
control population, the increased risk was
lowest among patients who had undergone appendectomy because of non-perforated appendicitis. It is not known what the risk of subsequent small bowel obstruction would be in
patients with acute appendicitis managed nonoperatively.
Given these data, the traditional operative
approach to patients with acute appendicitis
seems an excellent option. What would be the
benefit of testing an option of nonoperative
management? Given that mortality and morbidity related to the operative procedure is already quite low, it is likely that only outcomes
such as the cost of therapy or the time to full
recovery could be addressed feasibly. Nonetheless, further examination of the issue may be
worthwhile. In the United States, there has
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been a widespread increase in the use of diagnostic imaging techniques, particularly the use
of computerized tomographic (CT) imaging of
the abdomen, to evaluate patients with abdominal pain. This use may be triggering an
operation in patients with fairly mild acute appendicitis, who, in the past, were observed clinically and ultimately treated nonoperatively.
Obviously, additional data are needed to determine whether or not this conjecture is true.
However, this increased use of abdominal
imaging may improve knowledge of the natural history of early appendicitis and thereby
allow objective identification of lower-risk patients who might be treated appropriately using a nonoperative approach.
Antimicrobial therapy for lower-risk patients with
intra-abdominal infections
The standard principle of antimicrobial therapy for intra-abdominal infections is that the
agents used should be active against both the
aerobic/facultative anaerobic, gram-negative
bacilli and obligate anaerobic organisms that
are found as a component of the normal gut
flora, and that account for most of these
polymicrobial infections [2,3,5]. A number of
TABLE 2.

RECOMMENDED ANTIMICROBIAL AGENTS

SIS Guidelines [3]

agents have been shown to be effective for
treating patients with complicated intra-abdominal infections in prospective, randomized,
controlled trials. Indeed, this is one area in
which there are sufficient Class I data to develop firm recommendations. Although there
are far fewer prospective data evaluating antimicrobial therapy for patients with intra-abdominal infections treated non-operatively,
presumably these same agents would be effective for treating patients with uncomplicated
intra-abdominal infections.
Guidelines for the use of antimicrobial
agents for intra-abdominal infections have
been promulgated by both the SIS [3,4], and the
Infectious Diseases Society of America (IDSA)
[5] (Table 2). The IDSA recommendations specified a set of antimicrobials for the treatment of
patients with mild-to-moderate infections. In
contrast, the SIS guidelines did not specify
which agents to use in lower-risk patients with
community-acquired infections, but suggested
that agents with a narrower spectrum of activity, lower toxicity, and lower cost were preferable for these patients. Examples cited included
anti-anaerobic cephalosporins, ampicillin/sulbactam, and ticarcillin/clavulanic acid, but
were not limited to those agents.

FOR

PATIENTS

WITH INTRA-ABDOMINAL INFECTIONS

IDSA Guidelines [5]
(mild-to-moderate severity communityacquired infections)

Ampicillin/sulbactam

Ampicillin/sulbactam

Piperacillin/tazobactam

Ticarcillin/clavulanic acid

Ticarcillin/clavulanic acid

Ertapenem

Ertapenem

Cefazolin or cefuroxime plus metronidazole

Imipenem/cilastatin

Ciprofloxacin, levofloxacin, moxifloxacin, or
gatafloxacin plus metronidazole

Meropenem
Cefotetan
Cefoxitin
Gentamicin, tobramycin, netilmicin, or amikacin plus
an anti-anaerobe (clindamycin or metronidazole)
Cefuroxime plus metronidazole
Third/fourth-generation cephalosporin (cefotaxime,
ceftriaxone, ceftizoxime, ceftazidime, cefepime)
plus an anti-anaerobe
Ciprofloxacin plus metronidazole
Aztreonam plus clindamycin
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Beyond these general guidelines, it is difficult to derive more specific recommendations.
The available evidence only identifies antimicrobial regimens that are effective for the treatment of patients with intra-abdominal infections, but does not provide much information
as to which agents are preferred. Given the
large number of agents available, there have
been relatively few direct comparisons. Moreover, because most registration trials have been
powered to demonstrate non-inferiority rather
than superiority, such comparisons can usually
not be made. The use of meta-analysis might
provide some insight when individual trials are
powered inadequately to detect significant differences. For example, a recent meta-analysis
re-analyzed the role of an aminoglycoside,
used in conjunction with an anti-anaerobic
agent, for the therapy of intra-abdominal infections [38]. This study concluded that aminoglycosides were less effective than newer
agents, a finding that contradicts the concept
that these agents are the “gold standard” of antimicrobial therapy for intra-abdominal infections. Further, there was poor documentation
of the side effects of aminoglycosides, particularly ototoxicity. A drawback to any metaanalysis, however, is that it is dependent on the
quality of the individual studies included for
analysis. In this particular analysis, it was
found that many of the studies included in the
meta-analysis, particularly those conducted
one to two decades ago, were of low quality,
thus compromising any conclusions that could
be drawn. Moreover, single-daily-dose administration of aminoglycosides has not been evaluated prospectively for therapy of intraabdominal infections, because comparator regimens used in registration trials of new agents
(which comprise the bulk of the Class I data)
must be approved by the U.S. Food and Drug
Administration (FDA). Nonetheless, a primary
role for aminoglycosides in the treatment of intra-abdominal infections could be questioned
on the basis of these results.
The development of bacterial resistance is
another challenge to be faced in selecting antimicrobial therapy for lower-risk patients with
intra-abdominal infections. Although it is of
considerable importance in patients with nosocomial intra-abdominal infections, which will
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be considered later, this issue is also germane
to patients with community-acquired infections. Increasing resistance of Bacteroides fragilis to a number of agents has been well documented, including clindamycin and anaerobic
cephalosporins, although its clinical importance is still debated [4,5]. Of more concern is
the increasing resistance of many gram-negative pathogens in general and of Escherichia coli
in particular. In a recent study from Germany,
Krobot et al. [36] found that 26% of all isolates,
26% of gram-negative isolates, and 22% of E.
coli isolates from patients with community-acquired infections were resistant to some commonly-used antimicrobial agents. This resulted
in at least some patients receiving potentially
ineffective empiric antimicrobial therapy,
which was a risk factor for treatment failure.
Thus, even with community-acquired infections, there is no room for complacency with
regard to emerging bacterial resistance.
Certainly, it is hoped that antimicrobials under development may aid in the struggle against
resistant organisms. However, there have been
few new developments in therapeutic agents for
gram-negative pathogens, although some newer
fluoroquinolones and carbapenems are now
available or undergoing clinical study. An agent
which may soon be available is tigecycline,
which is the first in a new class of antibiotics
known as glycylcyclines. This agent exhibits in
vitro activity against a variety of gram-positive,
gram-negative, and anaerobic bacteria, including a number of resistant pathogens [37]. Dartois et al. recently demonstrated non-inferiority
(i.e., therapeutic equivalence) of tigecycline
compared to imipenem-cilastatin for the treatment of patients with complicated intra-abdominal infections. Definitive recommendations cannot be made until the data have been
published in peer-reviewed manuscript form,
but tigecycline could represent the first new
agent from a novel antimicrobial class to be introduced in recent years that can be used as
monotherapy for the treatment of patients with
intra-abdominal infections. This agent might be
useful in the treatment of patients who are allergic to penicillin and other beta-lactam agents,
and those more likely to harbor resistant
pathogens because of its broad amtibacterial
spectrum of activity.
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Although newer bacterial agents may aid
temporarily in the treatment of resistant organisms, the real key is avoiding, or at least curtailing, the development of these organisms.
Raymond et al. [39] have outlined a series of
steps to be taken to decrease the development
of resistant organisms in surgical patients. As
indicated previously, the choice of antimicrobial agents for lower-risk patients with community-acquired organisms is important in this
regard, because a narrower-spectrum agent
would be less likely to induce resistance than
would a broad-spectrum agent. Moreover, although it is important that the agents are active against the common gram-negative and
anaerobic organisms typically associated with
intra-abdominal infections, additional antimicrobial therapy directed against Enterococcus or
against fungal organisms is of no apparent benefit for the lower-risk patient with a community-acquired infection [3,5]. Thus, the use of
an extended-spectrum antimicrobial agent or
the addition of another antimicrobial agent to
provide such coverage will likely only lead to
the development of further resistance.
Another approach to curtailing resistance
emphasized by Raymond et al. [39] is to stop
antimicrobials once the infection is cured. Unfortunately, there is relatively little data available with regard to an adequate duration of
therapy for patients with intra-abdominal infections. Schein et al. [14] recommended that
duration of therapy should be limited, with the
most serious infections being treated for only
three to five days, and more localized infections
(such as perforated appendicitis) being treated
for only 24–48 h. Their data indicated that such
a strategy was associated with few treatment
failures. A recent study by Gleisner et al. [40]
verified that a longer duration of antimicrobial
therapy for patients with intra-abdominal infections was not associated with a decrease in
infectious complications. Both the SIS and
IDSA guidelines support limiting duration of
therapy to no more than five to seven days. Despite this, prolonged use of antimicrobial therapy remains common. A common provision in
clinical trials in intra-abdominal infections is
a minimum five-day course of antimicrobial
therapy, allowing up to 14 days of therapy.
Thus, the belief that prolonged antimicrobial
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therapy is somehow beneficial seems to be particularly persistent.
Another concept that seems to have persisted
despite evidence to the contrary is that intravenous antimicrobial therapy is essential for
patients with intra-abdominal infections. An
oral regimen of ciprofloxacin plus metronidazole is as efficacious as an intravenous regimen
of the same agents once the patient is able
to tolerate oral medications [4]. Oral amoxicillin/clavulanic acid is another agent that has
been utilized in several trials, although its use
has not been studied as rigorously [4]. Greater utilization of oral antimicrobial regimens
would simplify the care of patients with intraabdominal infections and facilitate outpatient
treatment. However, regardless of whether oral
or intravenous antimicrobials are used, it is still
important to limit the overall duration of antimicrobial exposure. The total course of therapy must not be lengthened by the reflexive
writing of prescriptions for a certain number of
days (usually seven days). Thus, there is a crucial need to determine rigorously the optimal
duration of antimicrobial therapy for patients
with community-acquired intra-abdominal infections. This information could assist in delineating the role of oral antimicrobials in the
treatment of these lower-risk patients as well.
Overall, the challenges in management of
low risk patients with community-acquired
intra-abdominal infections are primarily those
of defining and developing strategies limiting
unnecessary over-treatment of the patients,
whether it be overly aggressive surgical intervention or inappropriate antimicrobial therapy. However, it is important to remain vigilant to the possibility of compromising patient
outcomes through utilization of more conservative treatment strategies. Changes to standard
management approaches should be undertaken in light of carefully performed clinical
studies documenting efficacy of less-aggressive
approaches.

MANAGEMENT OF HIGHER-RISK
PATIENTS
Although a primary challenge in the management of lower-risk patients with commu-
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nity-acquired intra-abdominal infections is to
decrease the potential morbidity of the interventions utilized to treat these patients, the
primary challenge faced in the treatment of
higher-risk patients is to improve clinical outcome, particularly mortality. Depending on the
specific criteria used to define these patients,
mortality rates are in the range of 17–32% [4].
There are many areas of controversy related to
the management of these patients, both with regard to the surgical and non-surgical treatments utilized, and the optimal therapeutic
strategies have not been standardized.
As discussed previously, there is no uniform
definition of what constitutes a higher-risk patient with an intra-abdominal infection. However, for the purposes of this discussion, emphasis will be placed on the patient at higher
risk because of: 1) compromised function of
critical organs engendered by the acute physiological response to the infection and the patient’s pre-existing medical conditions; 2) the
extent of the peritoneal infection and the difficulty in achieving primary source control; and
3) infection due to resistant pathogens acquired
nosocomially. Obviously, the distinction between these different sets of risk factors is
somewhat artificial, but this separation does allow the therapeutic approaches to be divided
into three general areas. For the first set of risk
factors, overall management strategies for the
patient with sepsis will be emphasized, for the
second set, approaches to source control will be
discussed, and for the third, the utilization of
appropriate antimicrobial therapy will be
stressed. However, these management strategies clearly overlap, and no one approach can
be employed in isolation from the others. These
aims correspond broadly to the treatment goals
outlined by Marshall [2] for these patients, as
discussed next.
In discussing management strategies for
higher-risk patients with intra-abdominal infections, an immediate challenge is the lack of
good clinical evidence for many of the therapies utilized. There is an increasing body of evidence regarding treatment of the patient with
sepsis, but very little of the data focus specifically on patients with intra-abdominal infections as a cause of sepsis. There are virtually no
prospective, randomized, controlled trials with
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respect to source control procedures for higherrisk patients with these infections. Finally, as
indicated previously, antimicrobial registration
trials have enrolled primarily lower-risk patients with community-acquired infections,
and extrapolating the results of such studies to
the treatment of higher-risk patients is problematic. Thus, most of the treatment approaches used in higher-risk patients with intra-abdominal infections have never been
tested rigorously, and it is therefore difficult to
develop firm recommendations with regard to
both the general and specific therapies used.
One of the challenges for the future, then, is to
perform studies in carefully defined, higherrisk patient subsets, so that treatment strategies
can be evaluated rigorously.
Management of sepsis in patients with
intra-abdominal infections
In outlining management principles for patients with intra-abdominal infections, Marshall emphasizes “timely hemodynamic resuscitation and support of vital organ function” in
addition to source control and appropriate antimicrobial therapy [2]. Although this was not
stressed in the description of treatment of
lower-risk patients with community-acquired
infections, it is of clear importance in the management of higher-risk patients. Many of these
patients have signs of severe sepsis with compromised vital organ function, and some have
septic shock. The essence of these therapeutic
interventions is the timely provision of critical
care appropriate for the patient with intra-abdominal sepsis.
A complete review of the treatment modalities used to treat patients with sepsis is beyond
the scope of this paper. However, many of
these management principles have been outlined in the Surviving Sepsis Campaign, a
series of recommendations developed by representatives from eleven international organizations, including the SIS [41]. Treatment recommendations relate to initial, goal-directed
resuscitation of the patient; the use of various
agents for hemodynamic support; strategies of
mechanical ventilation, fluid and blood product administration; control of hyperglycemia;
the use of intravenous corticosteroids; and the
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use of activated protein C (drotrecogen alfa (activated)), among others. Although these general
interventions will not be discussed in detail,
they should be considered of equal importance
to the specific source control procedures and
antimicrobial regimens utilized for treatment
of patients with sepsis causes by an intra-abdominal infection.
Some of the general interventions used for
treating patients with sepsis may need to be
modified when applied to the higher-risk patient with an intra-abdominal infection. Because of the risk of bleeding, for instance, it is
recommended that an infusion of activated
protein C be deferred (or postponed, if begun
already) for approximately 12 h after a major
invasive procedure, such as a laparotomy
needed for source control in a patient with a
complicated intra-abdominal infection. A further concern with the use of this agent in surgical patients has also been the subject of a recent FDA warning against using the drug in
postoperative patients with an APACHE II
score  25 and evidence of only single-organ
failure. Although the original data demonstrated improved survival in patients with
sepsis and failure of two or more organs who
received activated protein C, including those
who had undergone recent surgery [42], a review of more recent data in less severely ill
surgical patients with failure of only a single
organ showed that mortality was paradoxically higher. It is not known how many of
these surgical patients underwent an operation because of an intra-abdominal infection.
Nonetheless, it points to the need of careful
studies of specific interventions utilized in
higher-risk patients with intra-abdominal infections.
Source control for higher-risk patients with
intra-abdominal infections
The general principles of source control for
intra-abdominal infections, as outlined by Marshall [2] and described above, apply equally to
lower-risk and higher-risk patients. As with
lower-risk patients, it would be impossible to
discuss exhaustively the options for surgical
treatment of higher-risk patients with these infections. However, there are a few general
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trends in the use of source control procedures
for higher-risk patients that are worthy of note.
One aspect of surgical therapy that is particularly pertinent to higher-risk patients is the
utilization of a temporizing procedure versus
a definitive one, as discussed by Fry [43]. With
higher-risk patients, a prolonged surgical procedure may compromise further an already
compromised host. In contrast, the use of temporizing measures may allow the critically ill
patient to be stabilized, so that a definitive procedure may be performed under more favorable physiological conditions. Appropriate
temporizing procedures range from percutaneous drainage of the gallbladder for acute
cholecystitis, to performing a rapid bowel resection without re-establishment of gastrointestinal continuity (deferred anastomosis) in a
patient with an intestinal perforation. The use
of these temporizing procedures is analogous
to the performance of “damage control” laparotomy for patients with severe abdominal
trauma and the “lethal triad” of hypothermia,
coagulopathy, and acidosis.
The use of temporizing measures may be especially pertinent to patients at higher risk because of limited physiological reserves or
compromise of vital organs. However, as indicated previously, patients are also at higher
risk because of the extent of the intra-abdominal infection. As already discussed, the inability to achieve adequate source control,
which may itself be a consequence of the extent of the intra-abdominal infection, is a risk
factor for an adverse clinical outcome. The
management of infections developing in association with pancreatitis and the surgical treatment of patients with severe, generalized peritonitis will be discussed as an exemplar. A
description of the treatment of pancreatic infections must begin with the acknowledgment
that this infection occurs late in the course of
this acute inflammatory process. Thus, some
aspects of operative and nonoperative management of patients with necrotizing pancreatitis may pertain to the treatment of the patient before an intra-abdominal infection is
actually present. However, it seems reasonable to include these aspects of treatment in
the discussion, because they may have a direct impact on the development of an infec-
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tion and the subsequent need for specific procedures to control the infection.
A recent international consensus conference
developed some management guidelines for
the treatment of critically ill patients with severe acute pancreatitis [44]. These recommendations will be taken as a starting point for this
discussion. As with most questions relating to
the appropriate therapy for higher-risk patients
with intra-abdominal infections, most of these
recommendations could not be based on large,
prospective, randomized, controlled studies.
Where such studies did exist, they actually provided somewhat conflicting data. One issue
concerns the indications and timing of surgical
procedures for the treatment of patients with
necrotizing pancreatitis. Although the evidence
was not definitive, the conference guidelines
called for pancreatic debridement/drainage
only in patients for whom the presence of an
infection had been established by either a positive culture of the area of pancreatic necrosis
obtained by fine needle aspiration, or by radiographic criteria such as the presence of gas in
the area of pancreatic necrosis. The guidelines
also suggested that such procedures are optimally delayed until two or three weeks after
the development of severe acute pancreatitis,
in order to allow for better demarcation of areas of necrosis. Routine debridement of pancreatic necrosis that is not infected was not recommended. Thus, these guidelines move away
from routine operative interventions for management of severe pancreatitis, and suggest
that aggressive source control procedures be
reserved for patients with a complicating pancreatic infection.
The use of prophylactic, broad-spectrum antibiotics for patients with pancreatic necrosis is
an issue that generates substantial controversy.
Although this question does not relate directly
to the use of specific source control procedures,
it could have a substantial indirect impact on
the need for such procedures. The use of broadspectrum antimicrobial prophylaxis could be
beneficial if it prevented the development of a
pancreatic infection and thereby eliminated the
need for operative debridement. However, if
this approach failed to prevent an infection, it
could lead to the selection of resistant pathogens and make the infection even more diffi-
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cult to treat, from both surgical and medical
perspectives [44].
Unfortunately, this is an issue for which
prospective trials have reached conflicting conclusions. Some earlier studies supported the
use of prophylactic, broad-spectrum, antimicrobial therapy in these patients, based on decreases in pancreatic infections, the need for operative debridement, or mortality. However,
the most recent prospective trial, which was
double-blind, found no such improvement in
outcome among patients randomized to receive prophylactic ciprofloxacin and metronidazole compared to those randomized to receive a placebo [45]. Examining the data in
aggregate, the consensus recommendation was
that broad-spectrum, prophylactic antimicrobial therapy should not be administered routinely to patients with pancreatic necrosis [44].
Additional data are needed.
Another issue that generates much controversy is the optimal surgical treatment of patients with severe, generalized, intra-abdominal infections, including those with persistent
or tertiary peritonitis. There has been some enthusiasm for routine re-exploration and abdominal irrigation for patients with severe, diffuse peritonitis. Wittmann et al. [46] suggested
that certain, very high-risk patients with severe
secondary peritonitis be treated with a program of multiple planned re-laparotomies,
with the decision to re-operate being based on
the operative findings at the time of the initial
procedure. Schein [47] suggests that the best indication for the use of planned re-laparotomy
is an inability to achieve source control at the
time of the initial intervention. Additional indications may be for patients with poorly localized infections requiring multiple debridements, and for patients with an overwhelming
amount of peritoneal contamination/infection.
There are no large prospective trials available to judge the results of routine, planned relaparotomy for patients with severe intra-abdominal infections. Most of the studies that
have been reported are retrospective and either
uncontrolled or poorly controlled. Several have
found no improvement in clinical outcome using planned re-laparotomy [8,48,49], whereas
others have suggested a benefit to routine reexploration [50,51]. Obviously, this is another
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area where there is an unmet need for well-designed prospective trials to evaluate this approach to these higher-risk patients.
Antimicrobial therapy for higher-risk patients
with intra-abdominal infections
For lower-risk patients with community-acquired intra-abdominal infections, the specific
antimicrobial regimen selected does not appear
to have a major impact on outcome, as long as
appropriate agents are utilized. In contrast,
antimicrobial selection may play a much more
important role in the treatment of higher-risk
patients. For instance, as already described, isolation of microorganisms resistant to the initial
empiric antimicrobial regimen was identified
as a risk factor for mortality among patients
with postoperative intra-abdominal infections
[17]. Resistant microorganisms are increasingly
isolated from patients with intra-abdominal infections as their length of hospitalization, and
particularly their exposure to prior antimicrobial therapy, increases. In patients with persistent or tertiary peritonitis, the predominant
pathogens are nosocomial microorganisms,
such as Pseudomonas sp., enterococci, staphylococci, and Candida sp. [52,53], rather than the
gram-negative Enterobacteriaceae and anaerobic
organisms typical of secondary peritonitis.
The antimicrobial regimens recommended in
the SIS and IDSA guidelines for higher-risk patients with intra-abdominal infections are listed
in Table 3. These regimens include agents with
a broader spectrum of activity against gramnegative and anaerobic organisms than those

TABLE 3.

RECOMMENDED ANTIMICROBIAL AGENTS

FOR

utilized in lower-risk patients with communityacquired infections. In general, these regimens
will provide adequate activity against most of
the common organisms isolated in higher-risk
patients, even those with intra-abdominal infections acquired nosocomially [54]. Nonetheless,
additional antimicrobial therapy should be considered for higher-risk patients who are believed
likely to be harboring resistant microorganisms.
A major challenge is identifying such patients
so that empiric antimicrobial regimens are designed to have activity against an expected set
of pathogens. Some of the general principles of
antimicrobial therapy for resistant gram-negative, gram-positive, and fungal microorganisms
will now be outlined.
With respect to gram-negative organisms acquired nosocomially, one problem faced increasingly is the growing resistance of these organisms to many antibiotics that are available
currently. This was studied in isolates of Enterobacteriaceae and of the non-fermentative,
gram-negative bacilli, Pseudomonas aeruginosa
and Acinetobacter baumannii, obtained over a
period of several years in the United States
[55,56]. Increasing resistance to fluoroquinolones, such as ciprofloxacin, was common
among all gram-negative pathogens, and there
was also increasing resistance of P. aeruginosa
to gentamicin, but not to amikacin. Another recent development is the identification of strains
of P. aeruginosa that are resistant to virtually all
anti-pseudomonal antibiotics. It has been necessary to resort to treatment with colistin to salvage patients infected with these highly-resistant strains [57].

PATIENTS

AT

HIGHER RISK DUE

TO INTRA-ABDOMINAL INFECTION

SIS Guidelines [3]
(Higher-risk patients)

IDSA Guidelines [5]
(high-severity, community-acquired infections)

Imipenem/cilastatin

Imipenem/cilastatin

Meropenem

Meropenem

Piperacillin/tazobactam

Piperacillin/tazobactam

An aminoglycoside plus an anti-anaerobe

Aztreonam plus metronidazole

Aztreonam plus clindamycin

Ciprofloxacin plus metronidazole

Ciprofloxacin plus metronidazole

A third/fourth-generation cephalosporin
plus metronidazole

A third/fourth-generation cephalosporin
plus an anti-anaerobe
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For patients with serious nosocomial infections due to P. aeruginosa, there is an ongoing
debate regarding the utility of treating the organism with a combination of an aminoglycoside and a cell wall-active agent, such as an
anti-pseudomonal penicillin, cephalosporin, or
carbapenem. Combination therapy was tested
in two clinical trials of severely ill patients with
intra-abdominal infections, but did not prove
beneficial in either [58,59]. Thus, the SIS guidelines recommend against the use of combination therapy for higher-risk patients with serious intra-abdominal infections.
The problem of resistance among gramnegative organisms producing nosocomial intra-abdominal infections is likely to remain a
challenge into the foreseeable future. Unfortunately, there does not appear to be many new
antimicrobial agents on the horizon that are intrinsically active against resistant, gram-negative organisms, particularly P. aeruginosa. Thus,
measures to decrease the transmission of
highly-resistant pathogens, such as adherence
to standard infection control practices, are of
great importance. If organisms such as the panresistant strains of P. aeruginosa become widespread, it will greatly complicate management
of patients with nosocomial intra-abdominal
infections.
The gram-positive organisms involved in
nosocomial, intra-abdominal infections are enterococci and staphylococci. Although Enterococcus spp. are isolated occasionally as part of
the polymicrobial flora found with communityacquired intra-abdominal infections, enterococci appear to play a much greater role in
infections acquired nosocomially. Routine
treatment of Enterococcus spp. is not recommended for most patients with community-acquired intra-abdominal infections, with the
possible exception of patients with serious
valvular heart disease or prosthetic valves, who
might be at risk for endocarditis in the event of
enterococcal bacteremia [60].
For higher-risk patients with nosocomial intra-abdominal infections, treatment of Enterococcus spp. is likely of greater importance. Isolation of Enterococcus spp. is more common in
patients with nosocomial intra-abdominal infections [17], and their isolation is a risk factor
for treatment failure and death [61–63]. Inade-
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quate empiric antimicrobial therapy is also
a risk factor for treatment failure and death
in patients with intra-abdominal infections
[6,17,36] and is a strong predictor of mortality
in critically ill patients with nosocomial pneumonia [64]. Thus, it would seem reasonable to
cover Enterococcus spp. empirically in higherrisk patients who are likely to harbor nosocomial pathogens. Such patients may include
those with prior exposure to antimicrobials and
those with complex infections of small- or
large-bowel origin. Enterococcal coverage
could be provided through the selection of
agents that have intrinsic enterococcal coverage, such as some penicillins and carbapenems,
or by the addition of an anti-enterococcal penicillin or vancomycin to regimens that lack enterococcal coverage. Specific anti-enterococcal
therapy should not be continued in patients
whose intra-abdominal cultures are negative
for this organism, however.
The development of vancomycin-resistant
strains of Enterococcus, particularly E. faecium,
presents a new dilemma. Fortunately, intra-abdominal infections due to this microorganism
are relatively uncommon. Several newer antimicrobial agents, including linezolid and daptomycin, are effective against vancomycin-resistant enterococci (VRE). Tigecycline also has
in vitro activity against VRE [37]. Empiric therapy directed against VRE has not been tested,
and cannot be recommended at the present
time. The use of agents active against VRE
should be reserved for patients who have culture-proven evidence of an infection due to this
organism.
Staphylococci are rarely isolated from patients with community-acquired intra-abdominal infections, but are isolated with increased
frequency from patients with postoperative infections [17], pancreatic infections [65], or tertiary peritonitis [52,53]. Both coagulase-negative and coagulase-positive staphylococci have
been recovered from patients with nosocomial
intra-abdominal infections, although the pathogenic role of the former has been questioned
[66]. There has been little published with respect to antimicrobial therapy for patients with
intra-abdominal infections due to staphylococci.
Many of the antimicrobials recommended for
treatment of intra-abdominal infections in
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higher-risk patients, such as piperacillin/
tazobactam, carbapenems, and several third-/
fourth-generation cephalosporins have some activity against methicillin-sensitive Staphylococcus aureus. However, these agents are not generally considered first-line therapy for this
pathogen. The use of an anti-staphylococcal
penicillin would seem reasonable for patients
with serious intra-abdominal infections due to
this organism, especially if the patient had
an associated bacteremia. For patients with a
non-anaphylactoid penicillin allergy, a firstgeneration cephalosporin may be used because
the incidence of cross-reactivity is only approximately 5%. Alternatively, vancomycin
may be used.
For patients with methicillin-resistant Staphylococcus aureus (MRSA), the choices are more limited. Vancomycin is still probably the first line
agent for this organism. However, there is
some evidence that linezolid is more effective
than vancomycin against this organism in critically ill patients with nosocomial pneumonia,
and in other patients with skin and soft tissue
infections [67,68]. It is unknown if this also applies to patients with intra-abdominal infections due to this organism. Quinupristin/dalfopristin and daptomycin are alternative
agents with activity against MRSA [69,70], but
experience in the treatment of intra-abdominal
infections with these antimicrobials is quite
limited as well. Tigecycline also has in vitro activity against MRSA, and has been studied in
both skin and soft tissue infections and lowerrisk intra-abdominal infections.
Vancomycin is the mainstay of therapy for
patients with intra-abdominal infections due to
coagulase-negative staphylococci, if that organism is to be treated. Most isolates of coagulasenegative Staphylococcus are resistant to antistaphylococcal penicillins and cephalosporins.
Although linezolid, daptomycin, and quinupristin/dalfopristin have activity against
these gram-positive organisms in vitro [71,72],
there is little clinical data available to make
therapeutic recommendations regarding use of
these agents for patients with intra-abdominal
infections. Tigecycline also has in vitro activity
against coagulase-negative staphylococci.
A final issue with regard to higher-risk patients with nosocomial intra-abdominal infec-
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tions is the treatment of fungal pathogens,
primarily Candida albicans. Although these
organisms are isolated with some frequency
from patients with community-acquired infections, antifungal therapy is not necessary in
that setting. Isolation of Candida spp. is primarily a concern when isolated from higherrisk patients, particularly those with nosocomial intra-abdominal infections. Antifungal
therapy is not recommended for lower-risk patients with community-acquired infections,
even when abdominal cultures are positive for
Candida [3,5]. However, for higher-risk patients, and particularly those with nosocomial
intra-abdominal infections, antifungal therapy
may be warranted when this organism is recovered. In one prospective, randomized, controlled trial [73], pre-emptive antifungal therapy with fluconazole was tested in patients at
high risk for Candida infections. This study
demonstrated a decreased incidence of Candida
peritonitis in the patients given pre-emptive
fluconazole therapy. However, this approach
has yet to be adopted universally. Its utilization is probably most appropriate at centers
where the incidence of intra-abdominal or
other infections due to Candida is high.
For patients with invasive candidal infections, several antifungal agents are now available. These include amphotericin B and its
lipid formulations, the azoles fluconazole and
voriconazole, and the echinocandins caspofungin and micafungin. The newer agents have
primarily been evaluated in patients with candidal blood stream infections, so their utility
for patients with candidal intra-abdominal infections has to be inferred from the results obtained from fungemic patients. There has been
some controversy regarding antifungal therapy
for patients with confirmed intra-abdominal infections due to Candida albicans. Based on very
limited data, it had been suggested that amphotericin B is more efficacious than fluconazole for treatment of these patients [74]. However, the toxicity of this agent, even in its lipid
formulations, makes the use of other agents
preferable [5,75]. It is unclear if the use of
voriconazole or caspofungin will supplant the
use of fluconazole for patients infected with
this organism. Some non-C. albicans species, especially C. glabrata and C. krusei, are less sus-
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ceptible to fluconazole. Although the use of
higher doses of fluconazole has been proposed
to treat these patients, the efficacy of this approach has not been proved [75]. These non-albicans species are susceptible to both voriconazole and caspofungin in vitro [76,77]. Thus,
these newer agents will likely be useful in the
treatment of intra-abdominal infections due to
these resistant candidal species, although there
is little published experience to date [5,75].
Clearly, a major challenge exists in selecting
appropriate antimicrobial regimens for higherrisk patients with intra-abdominal infections,
especially those with infections acquired nosocomially. These regimens should be based on
the suspected pathogens in a given patient. A
better understanding of how specific risk factors influence the likelihood of infection with
specific nosocomial pathogens could thereby
facilitate the selection of antimicrobial therapy.
Ultimately, however, this knowledge will have
to be combined with knowledge of local, institutional, and unit-specific trends in the types
of nosocomial pathogens encountered and
their resistance patterns, so that an appropriate

TABLE 4.
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empiric antimicrobial regimen can be tailored
to a specific patient.
What, then, is the overall management strategy for the higher-risk patient with an intra-abdominal infection? It would seem reasonable to
base therapy on the specific risk factors that categorize the patient as being at higher risk. For
patients with severe sepsis or septic shock, interventions to maintain critical organ perfusion
and compensate for disordered organ function
would be of high priority. The guidelines outlined in the Surviving Sepsis Campaign guideline represent a reasonable initial approach to
the treatment of these patients. For patients
at higher-risk due to the extensive nature of
the intra-abdominal infection, source control
should be achieved in an expedient manner.
The use of temporizing measures rather than
definitive procedures may be quite important
in patients with disordered physiology. The
use of re-laparotomy, although controversial,
could be considered, particularly when it is not
possible to achieve adequate source control at
the time of the initial procedure. For patients
at higher risk due to the presence of resistant

MANAGEMENT

OF INTRA-ABDOMINAL INFECTIONS

Identifying Patient Risk
1) What are the appropriate endpoints to use for risk factor analysis?
2) What acute physiological changes and chronic medical problems actually determine patient risk? Can a
simplified system be devised that has the same predictive value as the APACHE II score?
3) Can a uniform system, such as the Mannheim Peritonitis Index, be used to characterize the extent of the
intra-abdominal infection?
4) What characteristics can be used to identify patients harboring nosocomial pathogens?
Management of the Lower-Risk Patient
1) Which intra-abdominal infections can be treated safely without performing a primary source control
procedure?
2) Can the morbidity of source control be reduced by performing less invasive or extensive procedures without
sacrificing a good clinical outcome?
3) Are all the standard antimicrobial regimens still appropriate in the face of increasing resistance of
community-acquired pathogens?
4) What is the optimal duration of antimicrobial therapy for patients with complicated intra-abdominal
infections?
5) What is the appropriate role for oral antimicrobial agents?
Management of the Higher-Risk Patient
1) How can the general principles for the management of severe sepsis be applied to the patient with an intraabdominal infection? Are there any components of the Surviving Sepsis Campaign guideline that need to be
modified in treating patients with intra-abdominal infections?
2) When should temporizing procedures be utilized for source control?
3) What is the role of scheduled repeat laparotomy?
4) When should antimicrobial coverage be broadened to treat resistant, nosocomial pathogens?
5) What antifungal agents are appropriate to use in patients with intra-abdominal infections, and when?
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nosocomial pathogens, the initial empiric regimen should be broad in spectrum, covering the
likely resistant pathogens in a given patient,
and then narrowed as soon as possible according to culture results. A regimen effective
against gram-negative bacilli and anaerobic
bacteria, with the specific agents selected according to the local patterns of gram-negative
resistance, is the basis of that therapy. Coverage of Enterococcus spp. should be added for
patients potentially infected with that organism, and pre-emptive antifungal therapy
should also be considered in selected patients.
The utility of this approach of directing management priorities based on the specific clinical risk factors of a given patient should be verified in prospective studies of higher-risk
patients with intra-abdominal infections.

CONCLUSION
In this review, an attempt has been made to
delineate some of the challenges faced in improving management of patients with intra-abdominal infections. This discussion has emphasized the concept that the needs of
lower-risk patients with community-acquired
infections are quite distinct from those of patients at higher risk due to their compromised
physiological status, the extent of their intraabdominal infection, or the presence of nosocomial pathogens. Within this context, the challenges have been grouped into three general
categories: 1) facilitating the identification of
higher-risk patients; 2) providing less morbid
source control procedures and minimally toxic,
short-duration, antimicrobial regimens for
lower-risk patients; and 3) developing optimal
treatment approaches to source control and antimicrobial therapy for higher-risk patients. Examples of some of the challenges in these different areas are listed in Table 4.
Most published articles conclude with a statement that further study is required, and it goes
without saying that a similar statement could
be made here. The challenges outlined in this
review are not revelatory, having been identified previously by other authors. However, answers are still sought. The ultimate challenge
faced in answering these research questions is

the most difficult: How to ensure that the appropriate investigations needed to answer these
research questions are actually performed. To
date, much of the high quality data on the management of intra-abdominal infections has been
generated directly or indirectly as a result of
large clinical trials funded by pharmaceutical
companies seeking approval of new antimicrobial agents. There is no question that these studies have expanded our knowledge base greatly
and have led to the adoption of improved therapies for patients with intra-abdominal infections. Nonetheless, many of the challenges outlined here require studies of interventions that
are likely to be of negligible commercial value.
Unfortunately, such studies have received relatively little public research support, even
though the solutions to these problems could
lead to improvements benefiting not only individual patients, but health care as a whole. The
challenge of promoting research into the effective management of patients with intraabdominal infections is one that requires the cooperation of many individuals and organizations, and will not be solved by isolated investigators working alone. For such efforts, the role
of scientific organizations such as the SIS is key.
Hopefully, these organizations will increasingly
serve not only as advocates of carefully done
clinical research, but also as the coordinators of
such investigations [78].
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